Signals, Powered By EquityPandit
Jubilant Life Sciences said that its subsidiary has got the final approval from the US health regulator for Bupropion Hydrochloride extended release tablets that are used in treating major depressive disorder and prevention of seasonal affective disorder.
Jubilant Life Sciences said in a BSE filing that “Jubilant Pharma Ltd… has received abbreviated new drug application (ANDA) final approval for Burpropion Hydrochloride extended release tablets USP (XL), 150 mg and 300 mg.”
It added that this is the fourth approval that has been received by the company from the USFDA during the current financial year.
